Coronary Arterial Drug-Eluting Stent: From Structure to Clinical

Wu, Tingting; McCarthy, Stephen P.

doi:10.5772/30563

Cited by 5 publications

(5 citation statements)

References 144 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially, BMSs made up of steel were used, followed by the development of drug-eluting stents (DESs) and bioresorbable stents (BRSs) (Tomberli et al, 2018). At present, thin-strut DESs, made of high-strength metallic alloys such as Co-Cr alloy and coated with drugs, are predominantly used for coronary arteries due to their effectiveness in the prevention of in-stent restenosis (compared to bare-metal stents) and late-stent thrombosis (compared to stents with thicker struts) (Wu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

A comparative study of microstructures and nanomechanical properties of additively manufactured and commercial metallic stents

Langi

Zhao

Jamshidi

et al. 2022

Materials Today Communications

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A comparative study of microstructures and nanomechanical properties of additively manufactured and commercial metallic stents

Langi

Zhao

Jamshidi

et al. 2022

Materials Today Communications

View full text Add to dashboard Cite

“…Stenting of arteries became a common treatment of cardiovascular medicine, enabling the re-opening of the narrowed vessels and restoring the normal blood flow. Current technologies, especially very promising and rapid development of drug eluting stents (DES), demonstrate good efficacy with a low rate of treatment failure, making it possible to also expand the stent application to patients with complicated diseases [1]. However, complications, such as in-stent restenosis, late thrombosis, local chronic inflammation, and re-occlusion rates, are still results of stent implantations [2], so that further development of stent devices and deep analysis of their long-term stability and failure mechanisms is necessary.…”

Section: Introductionmentioning

confidence: 99%

“…However, complications, such as in-stent restenosis, late thrombosis, local chronic inflammation, and re-occlusion rates, are still results of stent implantations [2], so that further development of stent devices and deep analysis of their long-term stability and failure mechanisms is necessary. The restenosis rate of high-risk patients having small vessels, diabetes and long diffusion diseased arteries still remains unacceptably high ((30-60%) in bare-metal stents (BMS) and (6-18%) in DES) [1], demonstrating the challenge of stent technology and the need for new, more safe solutions for all patient categories.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Manufacturing Innovative Stents

et al. 2020

View full text Add to dashboard Cite

Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions.

show abstract

“…Arterial stent placement is becoming a standard cardiovascular treatment, allowing re-opening of narrowed vessels and restoring normal blood flow. The current technology, especially the up-and-coming and rapidly developing drug-eluting stent (DES), shows good effectiveness with a low treatment failure rate, making it possible to expand the application of stents in patients with severe disease [2].…”

Section: Introductionmentioning

confidence: 99%

Biomedical Material for Stent Application: Current Status and Future Challenges

Sukmana

Chyanegoro

Sugiri

2021

J.ASET

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. Arterial stenting as a transluminal angioplasty procedure allows re-opening of narrowed vessels and restoring normal blood flow with stent placement. The development of stents ed at the end of 19 century with bare-metal stents (BMS). Now, it has been based on the application of biodegradable or natural decomposed and coated stents. The coated stent has been found to improve BMS properties in terms of biocompatibility, cytotoxicity, and better mechanical and biophysical properties. Also, a biodegradable stent may support the blood micro-vessel during the estimated period of time before downgraded constituents. The biodegradable stent also allows a reinsertion for several months to improve the vessel wall's quality. This paper describes the possible materials for stents and their properties such as design criteria, degradation behavior, disadvantages, and advantages with clinical and preclinical trials to date. Stent degradation allows reinsertion of the stent after several months and improves the vessel wall quality. This paper focuses on developing materials for stents, which describe the possible materials for stents and their properties. Furthermore, the current clinical trial of the new proposed stent will also be highlighted.

show abstract

Coronary Arterial Drug-Eluting Stent: From Structure to Clinical

Cited by 5 publications

References 144 publications

A comparative study of microstructures and nanomechanical properties of additively manufactured and commercial metallic stents

A comparative study of microstructures and nanomechanical properties of additively manufactured and commercial metallic stents

Recent Advances in Manufacturing Innovative Stents

Biomedical Material for Stent Application: Current Status and Future Challenges

Contact Info

Product

Resources

About